Hammond Sean L, Leek Ashley N, Richman Evan H, Tjalkens Ronald B
Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO, United States of America.
Department of Biomedical Sciences, Colorado State University, Fort Collins, CO, United States of America.
PLoS One. 2017 Dec 15;12(12):e0188830. doi: 10.1371/journal.pone.0188830. eCollection 2017.
The non-pathogenic parvovirus, adeno-associated virus (AAV), is an efficient vector for transgene expression in vivo and shows promise for treatment of brain disorders in clinical trials. Currently, there are more than 100 AAV serotypes identified that differ in the binding capacity of capsid proteins to specific cell surface receptors that can transduce different cell types and brain regions in the CNS. In the current study, multiple AAV serotypes expressing a GFP reporter (AAV1, AAV2/1, AAVDJ, AAV8, AAVDJ8, AAV9, AAVDJ9) were screened for their infectivity in both primary murine astrocyte and neuronal cell cultures. AAV2/1, AAVDJ8 and AAV9 were selected for further investigation of their tropism throughout different brain regions and cell types. Each AAV was administered to P0-neonatal mice via intracerebroventricular injections (ICV). Brains were then systematically analyzed for GFP expression at 3 or 6 weeks post-infection in various regions, including the olfactory bulb, striatum, cortex, hippocampus, substantia nigra (SN) and cerebellum. Cell counting data revealed that AAV2/1 infections were more prevalent in the cortical layers but penetrated to the midbrain less than AAVDJ8 and AAV9. Additionally, there were differences in the persistence of viral transgene expression amongst the three serotypes examined in vivo at 3 and 6 weeks post-infection. Because AAV-mediated transgene expression is of interest in neurodegenerative diseases such as Parkinson's Disease, we examined the SN with microscopy techniques, such as CLARITY tissue transmutation, to identify AAV serotypes that resulted in optimal transgene expression in either astrocytes or dopaminergic neurons. AAVDJ8 displayed more tropism in astrocytes compared to AAV9 in the SN region. We conclude that ICV injection results in lasting expression of virally encoded transgene when using AAV vectors and that specific AAV serotypes are required to selectively deliver transgenes of interest to different brain regions in both astrocytes and neurons.
非致病性细小病毒——腺相关病毒(AAV)是一种在体内高效表达转基因的载体,在临床试验中显示出治疗脑部疾病的潜力。目前,已鉴定出100多种AAV血清型,其衣壳蛋白与特定细胞表面受体的结合能力不同,这些受体可转导中枢神经系统中的不同细胞类型和脑区。在本研究中,筛选了多种表达绿色荧光蛋白(GFP)报告基因的AAV血清型(AAV1、AAV2/1、AAVDJ、AAV8、AAVDJ8、AAV9、AAVDJ9)在原代小鼠星形胶质细胞和神经元细胞培养物中的感染性。选择AAV2/1、AAVDJ8和AAV9进一步研究它们在不同脑区和细胞类型中的嗜性。通过脑室内注射(ICV)将每种AAV给予出生后第0天的新生小鼠。然后在感染后3周或6周对大脑的各个区域,包括嗅球、纹状体、皮质、海马、黑质(SN)和小脑,系统地分析GFP表达。细胞计数数据显示,AAV2/1感染在皮质层中更普遍,但与AAVDJ8和AAV9相比,其向中脑的渗透较少。此外,在感染后3周和6周,体内检测的三种血清型之间病毒转基因表达的持久性存在差异。由于AAV介导的转基因表达在帕金森病等神经退行性疾病中受到关注,我们用显微镜技术,如CLARITY组织转化技术,检查了黑质,以确定在星形胶质细胞或多巴胺能神经元中导致最佳转基因表达的AAV血清型。与SN区域中的AAV9相比,AAVDJ8在星形胶质细胞中表现出更多的嗜性。我们得出结论,当使用AAV载体时,脑室内注射可导致病毒编码的转基因持续表达,并且需要特定的AAV血清型来将感兴趣的转基因选择性地递送至星形胶质细胞和神经元中的不同脑区。